trastuzumab
Showing 1 - 25 of 1,505
Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)
Active, not recruiting
- Malignant Solid Neoplasm
- Biopsy
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Nov 15, 2023
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,
Not yet recruiting
- Her 2 Positive Breast Cancer
- +2 more
- Sacituzumab Govitecan
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 25, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copper Cu 64-DOTA-Trastuzumab
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Active, not recruiting
- Breast Cancer
- Pyrotinib Plus Trastuzumab
- Pertuzumab Plus Trastuzumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 5, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +5 more
- Trastuzumab
- +2 more
-
Scottsdale, Arizona
- +2 more
Jan 31, 2023
GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)
Recruiting
- GastroEsophageal Cancer
- Gastric Cancer
- Neratinib
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 25, 2023
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)
Not yet recruiting
- Stomach Neoplasm
- Trastuzumab deruxtecan
- Afatinib
- (no location specified)
Oct 16, 2023
Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)
Completed
- Advanced Gastric Carcinoma
- Trastuzumab
- +2 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Aug 15, 2023
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and
Recruiting
- Early-stage Breast Cancer
- +4 more
- Trastuzumab and nelatinib
- Trastuzumab and Parstuzumab
-
Guangzhou, ChinaSun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +4 more
- Necitumumab
- +4 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023
Safety and Efficacy of Trastuzumab BS
Not yet recruiting
- Gastric Cancer
- TRASTUZUMAB BS
- (no location specified)
Dec 19, 2022
t Pathologic Complete Response Observed in HER2 Positive Breast
Completed
- HER2+ Breast Cancer
- Trastuzumab
-
Rawalpindi, Punjab, PakistanRawalpindi Medical University
Jun 26, 2023
Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)
Recruiting
- Brain Cancer
- +4 more
- Trastuzumab deruxtecan
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,
Completed
- HER2 Positive Breast Carcinoma
- +6 more
- Utomilumab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 22, 2022
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)
Recruiting
- Breast Cancer
- pyrotinib combined with trastuzumab, dalpiciclib and letrozole
-
Yantai, Shandong, ChinaYantai Yuhuangding Hospital
Mar 23, 2023
Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)
Recruiting
- Breast Cancer
- Neoadjuvant
- pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel
-
Wuhan, Hubei, China
- +1 more
Aug 18, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)
Recruiting
- Breast Cancer
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Jun 1, 2023